(Susanne Posel) Obama signed an executive order entitled, “HIV Care Continuum Initiative” that will create a national movement and federal involvement in the war on HIV/AIDS.
This EO will “coordinate Federal efforts in response to recent advances regarding how to prevent and treat HIV infection. The Initiative will support further integration of HIV prevention and care efforts; promote expansion of successful HIV testing and service delivery models; encourage innovative approaches to addressing barriers to accessing testing and treatment; and ensure that Federal resources are appropriately focused on implementing evidence-based interventions that improve outcomes along the HIV care continuum.”
Enforcement of mandatory HIV testing for “all individuals ages 15 to 65 years” will be overseen by the US Preventative Services Task Force, in coordination with the Department of health and Human Services (DHHS).
Michael Weinstein, president of AIDS Healthcare Foundation (AHF), remarked: “Actions speak louder than words. We have had other grand announcements from the White House on AIDS that turned out to be empty words. If indeed the President has finally understood the importance of this issue and will proactively address our concerns, then we will applaud that effort, but not until then. We have wasted 4 1/2 years trying to educate this president about the tragedy that is AIDS in the world. The war against AIDS has not been won – keep your promise. Mr. President play a real leadership role here and abroad – your legacy depends on it.”
In 2010, the National HIV/AIDS Strategy For the United States (NHAS) was released with the goal of:
• Reducing HIV incidence
• Increasing access to care and optimizing health outcomes
• Reducing HIV-related health disparities
The Obama administration has taken pharmaceutical corporations and investors contributions as defining factors to create a “broad range of perspectives” on policy as directed from the Office of National AIDS Policy (ONAP).
ONAP is tasked with creating “a national strategy is a concise plan” that will become “a document that provides a roadmap for policymakers and the general public.”
ONAP has taken steps within the public sector to facilitate “community discussions” in cities across the nation to formulate needs of those afflicted with HIV/AIDS; such as medical care and housing.
Kathleen Sebelius, Secretary for the DHHS, and Valerie Jarrett, senior advisor to Obama, have issued a statement claiming that “scientific developments have advanced our understanding of how to best fight HIV” and “recent research also shows that an important benefit of earlier treatment is that it dramatically reduces the risk of HIV transmission to partners. Furthermore, HIV testing technology is faster, and more accurate than ever before, and HIV drug treatment is less toxic, and easier to administer.”
Former Secretary of State, Hilary Clinton, announced last year that there was a blueprint to reign in the war against AIDS called President’s Emergency Plan for AIDS Relief (PEPFAR). Clinton explained that “HIV may well be with us into the future, but [AIDS] need not be.”
The US State Department is focused on an “AIDS-free generation” with a strong emphasis on testing and treatment. Clinton would like to see transmission brought to a minimum to ensure that with the proper measures taken, children will no longer be born with AIDS.
Scientists at the Imperial College at London have developed a nanotechnology that can be utilized in an HIV test for “better diagnosis and treatment in the developing world.”
Molly Stevens, lead researcher explains that this type of test analyzes saliva; however the acute sensitivity of this particular test will “be able to detect infection even in those cases where previous methods, such as the saliva test, were rendering a ‘false negative’ because the viral load was too low to be detected.”
This test identifies the HIV biomarker called p24; which if present will cause microscopic gold nanoparticles to clump together and turn a shade of blue. In contrast, a negative result will cause generate a red color.
Back in July, at the International AIDS Conference (IAC), there was a call for a coalition of international scientists working under the direction of UNAIDS to develop preventative measures, identifying human immune-responsive drugs and get them onto the market as quickly as possible.
Dr. Steven Deeks of the AIDS Research Institute, believes “that at best [its] 50-50 that we’re gonna get a cure” so preventative medicine is a better focal point.
By studying the “elite controllers” (people who are carriers, but do not display symptoms of HIV) scientists can decipher how the human immune system works and develop pharmaceuticals to administer to the public.
Trials conducted by Merck in 2007 actually made those who took the vaccine more susceptible to the disease. Then in 2009, human experiments in Thailand pointed to drug corporations toward a powerful vaccine that utilized immune system generated anti-bodies as the answer to their dilemma.
Earlier this year, the Food and Drug Administration (FDA) has approved Gilead Sciences’ Truvada, the first pharmaceutical drug to prevent the virus that causes AIDS.
Marketed as a preventative for people who at high risk of contracting HIV through sexual activies, Turvada is supported by public health advocates that believe this pill will slow down the spread of HIV. In America it is estimated that 1.2 million people have HIV. With this new antiviral drug, it is proposed that 240,000 HIV carriers will not be able to continue to spread the disease.
Gilead Sciences combined two separate drugs to create Truvada. The genetically engineering of the preventative is praised by the FDA to answer the assumption that condoms are not effective.
New vaccines focus on tricking the human body to reject the HIV/AIDS virus by manipulating the immune system. This mutation is suspected to be able to assist the human body in identifying and neutralizing the virus.
Scientific teams from various institutions like the Scripps Research Institute, the Rockefeller University, NIAID’s Vaccine Research Center and Duke University are closely following how they can use the human body’s immune system against the array of HIV strains that keep popping up.
US government intervention with the National Institutes of Health in 2005 identified the human immunodeficiency virus as the cause of AIDS. Dr. Barton Haynes, of Duke University and director of the Center for HIV/AIDS Vaccine Immunology (CHAVI) asserted that: “We know the face of the enemy.”
Colonel Nelson Michael, director of the US Military HIV Research Program at the Walter Reed Army Institute of Research, who led the government experimentation of the RV144 trial, commented that since Merck’s vaccine trials “had chilling effect” that uncircumcised males at increased risk for infection prior to exposure to the vaccine. The WRAIR went into Uganda, Kenya and Tanzania to conduct human experimentation of compromising the human immune system under the cover of HIV/AIDS research for vaccination purposes.
Hayes’ research showed that vaccinated men and women developed antibodies in the region of the virus’s outer coat; which suggests that this element should be further studied.
According to an annual volume of the Special Cancer Virus Program, human experimentation with cancer-causing and immunosuppressive viruses was essential. With the “gay plague” and “gay cancer’, such experiments were no longer necessary. The deaths of thousands of gay men proved with these viruses caused cancer, immunosuppression, and were sexually-transmissible between people.
Somehow, the eugenics aspect of the HIV/AIDS epidemic, which directly correlates to its origin and would be useful in finding its cure is completely ignored by mainstream media, medical communities and even some members of the alternative media. In July 2008, the mainstream propaganda released an article admitting that, strangely enough, “people of African descent are much more likely to have a genetic trait that makes them more susceptible to infection with the HIV virus.”
In 1962, the US Senate received a report concerning chemical and biological warfare. This is the government contract where HIV-like and Ebola-like viruses were bio-engineered by the US military and the bioweapons contracting lab Biomedics. They were producing viral cancer in monkeys that could then be used through genetic engineering to infect humans.
Robert Gallo, working with the National Cancer Institute, was part of this project. Millions of people are dying from this US sponsored government project to depopulate certain groups of people because of their ethnic heritage; and the US Congress knew about it, and endorsed its use.
These biological agents are classified as “non-lethal warfare” because the morality is not instantaneous. Rockefeller and Stanford globalist think-tanks came up with the concept of ethnic cleansing by way of prolonged infection so that the target and cause could not be correlated. Biologicals and chemicals provide this covert mass extermination. According to the global Elite, this form of depopulation is economically sound as a stand form of military “soft kill.”
Use of bioweapons and suppressive-immunological viruses like HIV are introduced into the general public, without possibility of traceable detection and effectively reduce the population.Studies into immune suppression, as a treatment for cancer are not only conducted with the expressed purpose of analyzing infectious viruses, but also developing antiviral potentials that can target specific aspects of the human body by genetic amplification.
HIV/AIDS has been developed as a bio-weapon of mass depopulation capabilities, but now the global Elite are stepping up their intention with their research into the abilities of the human immune system. Specifics could result in a “vaccine” that would cause the human immune system to become ineffective. By claiming there is a pandemic, the global Elite could justify the need for mass immunizations. This would leave every person inoculated under threat of becoming deathly ill from even simple exposure to the common cold.
This article first appeared @ Occupy Corporatism